Pharmaceutical group Elan has sold four non-core businesses for $70m.
The sell-off includes operations in Switzerland and Italy, and an office property in San Diego in the US.
Chief executive Kelly Martin says the deals are consistent with its strategy of focusing on core areas and developing its drug pipeline and help reposition Elan for the future.
